RV5 NCT02728869.

Trial name or title	"Safety, Reactogenicity and Immunogenicity of Heat‐stable Rotavirus Vaccine (HSRV) in Adults and Infants"
Methods	Phase I/II, randomized, single‐blind trial
Participants	Number: 100 Description: Healthy infants of either sex, 6 ‐ 8 weeks of age; healthy adults
Interventions	1. Hilleman Labs heat stable pentavalent vaccine 2. RV5 Schedule: 3 doses at 4‐week intervals
Outcomes	3. Any adverse event 4. Serious adverse events 5. Anti‐Rotavirus IgA sero‐response rate 7. Viral shedding
Starting date	June 2016 Completion: April 2017
Contact information	K Zaman, MBBS, PhD; International Center for Diarrheal Disease Research, Bangladesh
Notes	Location: Bangladesh Registration number: NCT02728869 Source of funding: MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.

BRV: bovine‐human reassortant vaccine; GMT: geometric mean titre; SAE: serious adverse event